Market Mechanics
From filing to price impact: microstructure, currency-normalised comparisons, walk-forward design.
Medtronic's $4.75m CEO sale lands as peers rerate
Medtronic's CEO and a MedSurg president sold $5.7m under 10b5-1 plans as the device group trades against a mixed healthcare backdrop.
Ferguson’s 8-insider selling cluster after a 1.25% rise
Ferguson disclosed 8 insider sellers on October 16 as housing stays weak and the stock trades near $231.61. Here is the read against peers.
Riskified's 65,000-share sale tests the rally
Riskified's field-ops chief sold 65,000 shares as the stock rallied. We set that against fraud-spending demand, peer positioning, and the cluster.
Bill Hocking sells EUR 2.0m as Galliford Try rallies
Galliford Try chief executive Bill Hocking sold EUR 2.0m after a 30% year-to-date rise, while UK construction stays weak and peers stay cautious.
SI-BONE CEO sells EUR 679k as spine stocks wobble
SI-BONE CEO Laura Francis sold EUR 679k under a 10b5-1 plan as spine names traded through a weak macro tape and analysts stayed constructive.
Nazara’s 4-insider buy, Rs 731 crore issue, and the stock
Nazara paired a Rs 731 crore preferential issue with 4 insider allotments. Here is how the gaming pivot, UK deal, and valuation fit together.
He Ningning buys EUR 1.77m of Q Technology stock
Q Technology drew two October buys from Chairman He Ningning as handset margins stayed tight and automotive cameras kept growing.
Gerard Perrier: 2 buys, 1 low, and a 6.2 score
Gerard Perrier’s insider cluster lands near a 52-week low as H1 growth holds up and peers trade richer. Here is the business read.
Harworth CFO Kitty Patmore sells EUR 256,744 into 187p bid
Harworth’s CFO sold into Peel’s 187p cash offer as UK property shares stayed weak and the takeover price pinned the stock near fair value.
Informa’s 11-insider buy cluster and the Clarion pivot
Informa directors bought at 860p as the group funds Clarion and leans into B2B events. The cluster matters, but the backdrop matters more.
Scientex’s two director buys and the Pulai test
Two directors bought about EUR 885,890 each in Scientex as packaging margins improve and Johor land adds a new test for the story.
AstraZeneca, oncology momentum and a quiet insider bid
AstraZeneca has oncology and FDA catalysts in motion, while CEO and chair buying earlier this month gives the stock a quieter tell.